121 related articles for article (PubMed ID: 35475287)
1. The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease.
Simmons BA; Tran C; Pham CM; Shriver EM
Plast Reconstr Surg Glob Open; 2022 Apr; 10(4):e4287. PubMed ID: 35475287
[TBL] [Abstract][Full Text] [Related]
2. Effects of Teprotumumab on Eyelid Retraction in Thyroid Eye Disease.
Al-Sharif EM; Zhou J; Shoji MK; Acuff K; Liu CY; Korn BS; Kikkawa DO
Ophthalmic Plast Reconstr Surg; 2024 May; ():. PubMed ID: 38722772
[TBL] [Abstract][Full Text] [Related]
3. Change in upper eyelid position after teprotumumab treatment for thyroid eye disease.
Rosenblatt TR; Chiou CA; Yoon MK; Lee NG; Wolkow N; Freitag SK
Orbit; 2024 Jun; 43(3):337-343. PubMed ID: 38466206
[TBL] [Abstract][Full Text] [Related]
4. Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab.
Ugradar S; Braun J; Wang Y; Zimmerman E; Douglas RS
Plast Reconstr Surg Glob Open; 2021 Sep; 9(9):e3809. PubMed ID: 34549003
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
6. Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population.
Diniz SB; Cohen LM; Roelofs KA; Rootman DB
Ophthalmic Plast Reconstr Surg; 2021 Nov-Dec 01; 37(6):583-591. PubMed ID: 33710036
[TBL] [Abstract][Full Text] [Related]
7. Teprotumumab improves light sensitivity in patients with thyroid eye disease.
Parunakian E; Ugradar S; Tolentino J; Malkhasyan E; Raika P; Ghaly J; Bisht C; Douglas RS
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; ():. PubMed ID: 38639788
[TBL] [Abstract][Full Text] [Related]
8. Teprotumumab for chronic thyroid eye disease.
Ozzello DJ; Dallalzadeh LO; Liu CY
Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
[TBL] [Abstract][Full Text] [Related]
9. Improvement of asymmetric thyroid eye disease with teprotumumab.
Ugradar S; Wang Y; Mester T; Kahaly GJ; Douglas R
Br J Ophthalmol; 2022 Jun; 106(6):755-759. PubMed ID: 33579690
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab.
Ho TC; Maamari RN; Kossler AL; Sears CM; Freitag SK; Reshef ER; Shinder R; Rootman DB; Diniz SB; Kahana A; Schlachter D; Do TH; Kally P; Turner S; Mokhtarzadeh A; Harrison AR; Hwang CJ; Kim HJ; Avila SA; Thomas DA; Magazin M; Wester ST; Lee WW; Clauss KD; Holds JB; Sniegowski M; Compton CJ; Briggs C; Malik AI; Lucarelli MJ; Burkat CN; Patel LG; Couch SM
Ophthalmic Plast Reconstr Surg; 2023 Mar-Apr 01; 39(2):150-155. PubMed ID: 36095848
[TBL] [Abstract][Full Text] [Related]
11. Influence of surgical approach for decompression on lower eyelid position in thyroid eye disease.
Thorne AW; Rootman DB
Orbit; 2020 Apr; 39(2):84-86. PubMed ID: 31021263
[No Abstract] [Full Text] [Related]
12. Teprotumumab in advanced reactivated thyroid eye disease.
Cheng OT; Schlachter DM
Am J Ophthalmol Case Rep; 2022 Jun; 26():101484. PubMed ID: 35321251
[TBL] [Abstract][Full Text] [Related]
13. Contralateral Mueller's muscle-conjunctiva resection: a therapeutic option in thyroid eye disease patients with unilateral eyelid retraction.
Saonanon P; Potita P
Orbit; 2020 Apr; 39(2):98-101. PubMed ID: 31162982
[No Abstract] [Full Text] [Related]
14. Customized Minimally Invasive Orbital Decompression Surgery Improves Lower Eyelid Retraction and Contour in Thyroid Eye Disease.
Pieroni Goncalves AC; Gupta S; Monteiro MLR; Douglas RS
Ophthalmic Plast Reconstr Surg; 2017; 33(6):446-451. PubMed ID: 27997462
[TBL] [Abstract][Full Text] [Related]
15. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
[TBL] [Abstract][Full Text] [Related]
16. Relationships between eyelid position and levator-superior rectus complex and inferior rectus muscle in patients with Graves' orbitopathy with unilateral upper eyelid retraction.
Byun JS; Lee JK
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):2001-2008. PubMed ID: 29959506
[TBL] [Abstract][Full Text] [Related]
17. Medical Therapy in Patients with Moderate to Severe, Steroid-Resistant, Thyroid Eye Disease.
Toro-Tobon D; Rachmasari KN; Bradley EA; Wagner LH; Tooley AA; Stokken JK; Stan MN
Thyroid; 2023 Oct; 33(10):1237-1244. PubMed ID: 37515425
[No Abstract] [Full Text] [Related]
18. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease.
Jain AP; Gellada N; Ugradar S; Kumar A; Kahaly G; Douglas R
Br J Ophthalmol; 2022 Feb; 106(2):165-171. PubMed ID: 33172865
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
20. Smartphone-Based Artificial Intelligence-Assisted Prediction for Eyelid Measurements: Algorithm Development and Observational Validation Study.
Chen HC; Tzeng SS; Hsiao YC; Chen RF; Hung EC; Lee OK
JMIR Mhealth Uhealth; 2021 Oct; 9(10):e32444. PubMed ID: 34538776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
